.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,021,236

« Back to Dashboard

Details for Patent: 5,021,236

Title: Method of enhancing NMR imaging using chelated paramagnetic ions bound to biomolecules
Abstract:Agents useful for influencing the relaxation times in NMR diagnostics, contain at least one paramagnetic, physiologically compatible complex salt comprising a chelate from an open-chain or cyclic complex-forming compound containing organic nitrogen, phosphorus, oxygen and/or sulfur, and a complexed ion of the lanthanide elements of atomic number 57-70 or of the transition metals of atomic numbers 21-29, 42 and 44, and, optionally, an inorganic or organic base or acid, wherein said chelate complex is bound to a biomolecule.
Inventor(s): Gries; Heinz (Berlin, DE), Rosenberg; Douwe (Berlin, DE), Weinmann; Hanns-Joachim (Berlin, DE), Speck; Ulrich (Berlin, DE), Mutzel; Wolfgang (Berlin, DE), Hoyer; Georg-Alexander (Berlin, DE), Pfeiffer, deceased; Heinrich (late of Berlin, DE)
Assignee: Schering Aktiengesellschaft (DE)
Filing Date:Mar 02, 1987
Application Number:07/020,300
Claims:1. A method of imaging body tissue in a patient, comprising subjecting the patient to NMR tomography and prior to performing the NMR tomography administering to the patient an effective amount of a pharmaceutical agent for affecting the relaxation times of atoms in body tissue undergoing NMR diagnosis, whereby image contrast is enhanced, said agent comprising an amount, effective to affect such relaxation times, of a paramagnetic, physiologically compatible chelate complex of an ion of a lanthanide element of atomic numbers 58-70 or of a transition metal of atomic numbers 21-29, 42, or 44, wherein said chelate complex is bound to a biomolecule effective to transport said chelate complex to a specific site in said patient; and a pharmaceutically acceptable carrier.

2. A method of claim 1, wherein the paramagnetic ion is Gd(III).

3. A method of claim 1, wherein the paramagnetic ion is Mn(II).

4. A method of claim 1, wherein the paramagnetic ion is iron.

5. A method of claim 1, wherein the paramagnetic ion is chelated by an aminopolycarboxylic acid.

6. A method of claim 1, wherein no free acid or free base groups are present in the chelate complex.

7. A method of claim 1, wherein a free acid or a free base group is present in the chelate complex.

8. A method of claim 1, wherein a free acid or a free base group of the chelate complex is in the form of a salt thereof with an inorganic or organic base or acid.

9. A method of claim 1, wherein the paramagnetic ion is chelated by an open-chain chelating agent.

10. A method of claim 1, wherein the paramagnetic ion is chelated by a cyclic chelating agent.

11. A method of claim 1, wherein said chelate complex is both a salt of said paramagnetic ion and the chelate complexing agent thereof, and also a salt with an inorganic or organic base or acid.

12. A method of claim 1, wherein said chelate complex is only a salt of said paramagnetic ion and the chelate complexing agent thereof and not also a salt of an inorganic or organic base or acid.

13. A method of claim 4, wherein the paramagnetic ion is Fe(II).

14. A method of claim 1, wherein the patient is a human.

15. A method of claim 1, wherein the chelate complex is nonionic.

16. A method according to claim 1, wherein said biomolecule is an immunoglobulin.

17. A method according to claim 1, wherein said biomolecule is a hormone.

18. A method according to claim 1, wherein said biomolecule is a protein.

19. A method according to claim 1, wherein said biomolecule is a peptide.

20. A method according to claim 1, wherein said biomolecule is a lipid.

21. A method of enhancing NMR imageability of a patient comprising administering to the patient an amount, effective to enhance NMR image contrast, of a physiologically compatible chelate complex of a paramagnetic ion wherein said chelate complex is bound to a biomolecule effective to transport said chelate complex to a specific site in said patient.

22. A method of claim 21, wherein the complex is formulated together with a pharmaceutically acceptable carrier.

23. A method of claim 22, wherein the paramagnetic ion is Gd(III).

24. A method of claim 22, wherein the paramagnetic ion is Mn(II).

25. A method of claim 22, wherein the paramagnetic ion is iron.

26. A method of claim 22, wherein the paramagnetic ion is chelated by an aminopolycarboxylic acid.

27. A method of claim 22, wherein no free acid or free base groups are present in the chelate complex.

28. A method of claim 22, wherein a free acid or a free base group is present in the chelate complex.

29. A method of claim 22, wherein a free acid or a free base group of the chelate complex is in the form of a salt thereof with an inorganic or organic base or acid.

30. A method of claim 22, wherein the paramagnetic ion is chelated by an open-chain chelating agent.

31. A method of claim 22, wherein the paramagnetic ion is chelated by a cyclic chelating agent.

32. A method of claim 22, wherein said chelate complex is both a salt of said paramagnetic ion and the chelate complexing agent thereof, and also a salt with an inorganic or organic base or acid.

33. A method of claim 22, wherein said chelate complex is only a salt of said paramagnetic ion and the chelate complexing agent thereof and not also a salt with an inorganic or organic base or acid.

34. A method of claim 23, wherein the paramagnetic ion is Fe(II).

35. A method of claim 22, wherein the patient is a human.

36. A method of claim 22, wherein the chelate complex is nonionic.

37. A method according to claim 22, wherein said biomolecule is an immunoglobulin.

38. A method according to claim 22, wherein said biomolecule is a hormone.

39. A method according to claim 22, wherein said biomolecule is a protein.

40. A method according to claim 22, wherein said biomolecule is a peptide.

41. A method according to claim 22, wherein said biomolecule is a lipid.

42. A method according to claim 22, wherein said ion is an element of atomic numbers 21-22, 42, 44 or 58-70.

43. A method of enhancing NMR imageability of a patient comprising administering to the patient an amount, effective to enhance NMR image contrast, of a physiologically acceptable chelate complex of a paramagnetic ion having as a ligand a complexing agent containing organic nitrogen, phosphorous, oxygen or sulfur, and wherein said chelate complex is bound to a biomolecule effective to transport said chelate complex to a specific site in said patient.

44. A method of claim 43, wherein the complex is formulated together with a pharmaceutically acceptable carrier.

45. A method of claim 44, wherein the paramagnetic ion is Gd(III).

46. A method of claim 44, wherein the paramagnetic ion is Mn(II).

47. A method of claim 44, wherein the paramagnetic ion is iron.

48. A method of claim 44, wherein the paramagnetic ion is chelated by an aminopolycarboxylic acid.

49. A method of claim 44, wherein no free acid or free base groups are present in the chelate complex.

50. A method of claim 44, wherein a free acid or a free base group is present in the chelate complex.

51. A method of claim 44, wherein a free acid or a free base group of the chelate complex is in the form of a salt thereof with an inorganic or organic base or acid.

52. A method of claim 44, wherein the paramagnetic ion is chelated by an open-chain chelating agent.

53. A method of claim 44, wherein the paramagnetic ion is chelated by a cyclic chelating agent.

54. A method of claim 44, wherein said chelate complex is both a salt of said paramagnetic ion and the chelate complexing agent thereof, and also a salt with an inorganic or organic base or acid.

55. A method of claim 44, wherein said chelate complex is only a salt of said paramagnetic ion and the chelate complexing agent thereof and not also a salt with an inorganic or organic base or acid.

56. A method of claim 47, wherein the paramagnetic ion is Fe(II).

57. A method of claim 44, wherein the patient is a human.

58. A method of claim 44, wherein the chelate complex is nonionic.

59. A method according to claim 44, wherein said biomolecule is an immunoglobulin.

60. A method according to claim 44, wherein said biomolecule is a hormone.

61. A method according to claim 44, wherein said biomolecule is a protein.

62. A method according to claim 44, wherein said biomolecule is a peptide.

63. A method according to claim 44, wherein said biomolecule is a lipid.

64. A method of claim 44, wherein said ion is an element of atomic numbers 21-29, 42, 44, or 58-70.

65. A method of conducting NMR imaging comprising NMR imaging a patient to whom there has been administered an amount, effective to enhance NMR image contrast, of a physiologically compatible chelate complex of a paramagnetic ion, wherein said chelate complex is bound to a biomolecule, effective to transport said chelate complex to a specific site in said patient, and whereby an NMR image of an enhanced contrast is obtained.

66. A method according to claim 65, wherein the complex is formulated together with a pharmaceutically acceptable carrier.

67. A method of claim 66, wherein the paramagnetic ion is Gd(III).

68. A method of claim 66, wherein the paramagnetic ion is Mn(II).

69. A method of claim 66, wherein the paramagnetic ion is iron.

70. A method of claim 66, wherein the paramagnetic ion is chelated by an aminopolycarboxylic acid.

71. A method of claim 66, wherein no free acid or free base groups are present in the chelate complex.

72. A method of claim 66, wherein a free acid or a free base group is present in the chelate complex.

73. A method of claim 66, wherein a free acid or a free base group of the chelate complex is in the form of a salt thereof with an inorganic or organic base or acid.

74. A method of claim 66, wherein the paramagnetic ion is chelated by an open-chain chelating agent.

75. A method of claim 66, wherein the paramagnetic ion is chelated by a cyclic chelating agent.

76. A method of claim 66, wherein said chelate complex is both a salt of said paramagnetic ion and the chelate complexing agent thereof, and also a salt with an inorganic or organic base or acid.

77. A method of claim 66, wherein said chelate complex is only a salt of said paramagnetic ion and the chelate complexing agent thereof and not also a salt with an inorganic or organic base or acid.

78. A method of claim 69, wherein the paramagnetic ion is Fe(II).

79. A method of claim 66, wherein the patient is a human.

80. A method of claim 66, wherein the chelate complex is nonionic.

81. A method according to claim 66, wherein said biomolecule is an immunoglobulin.

82. A method according to claim 66, wherein said biomolecule is a hormone.

83. A method according to claim 66, wherein said biomolecule is a protein.

84. A method according to claim 66, wherein said biomolecule is a peptide.

85. A method according to claim 66, wherein said biomolecule is a lipid.

86. A method of claim 66, wherein said ion is an element of atomic numbers 21-29, 42, 44 or 58-70.

87. A method of conducting NMR imaging comprising NMR imaging a patient to whom there has been administered an amount, effective to enhance NMR image contrast, of a physiologically compatible chelate complex of a paramagnetic ion having as a ligand a complexing agent containing organic nitrogen, phosphorous, oxygen or sulfur, wherein said chelate complex is bound to a biomolecule effective to transport said chelate complex to a specific site in said patient, and whereby an NMR image of enhanced contrast is obtained.

88. A method of claim 87, wherein the complex is formulated together with a pharmaceutically acceptable carrier.

89. A method of claim 88, wherein the paramagnetic ion is Gd(III).

90. A method of claim 88, wherein the paramagnetic ion is Mn(II).

91. A method of claim 88, wherein the paramagnetic ion is iron.

92. A method of claim 88, wherein the paramagnetic ion is chelated by an aminopolycarboxylic acid.

93. A method of claim 88, wherein no free acid or free base groups are present in the chelate complex.

94. A method of claim 88, wherein a free acid or a free base group is present in the chelate complex.

95. A method of claim 88, wherein a free acid or a free base group of the chelate complex is in the form of a salt thereof with an inorganic or organic base or acid.

96. A method of claim 88, wherein the paramagnetic ion is chelated by an open-chain chelating agent.

97. A method of claim 88, wherein the paramagnetic ion is chelated by a cyclic chelating agent.

98. A method of claim 88, wherein said chelate complex is both a salt of said paramagnetic ion and the chelate complexing agent thereof, and also a salt with an inorganic or organic base or acid.

99. A method of claim 88, wherein said chelate complex is only a salt of said paramagnetic ion and the chelate complexing agent thereof and not also a salt with an inorganic or organic base or acid.

100. A method of claim 91, wherein the paramagnetic ion is Fe(II).

101. A method of claim 88, wherein the patient is a human.

102. A method of claim 88, wherein the chelate complex is nonionic.

103. A method according to claim 88, wherein said biomolecule is an immunoglobulin.

104. A method according to claim 88, wherein said biomolecule is a hormone.

105. A method according to claim 88, wherein said biomolecule is a protein.

106. A method according to claim 88, wherein said biomolecule is a peptide.

107. A method according to claim 88, wherein said biomolecule is a lipid.

108. A method according to claim 88, wherein said ion is an element of atomic numbers 21-29, 42, 44 or 58-70.

109. A method of imaging body tissue in a patient, comprising subjecting the patient to NMR tomography and prior to performing NMR tomography administering to the patient an effective amount of a pharmaceutical agent for affecting the relaxation times of atoms in body tissues undergoing NMR diagnosis, whereby image contrast is enhanced, said agent comprising an amount, effective to affect such relaxation times, of a paramagnetic, physiologically compatible chelate complex of an ion and, as a ligand, an acyclic or cyclic complexing agent containing organic nitrogen, phosphorous, oxygen or sulfur, the complexed ion being an ion of an element of atomic numbers 21-29, 42, 44, or 58-70, and wherein said chelate complex is bound to a biomolecule effective to transport said chelate complex to a specific site in said patient; and a pharmaceutically acceptable carrier.

110. A method of claim 109, wherein the paramagnetic ion is Gd(III).

111. A method of claim 109, wherein the paramagnetic ion is Mn(II).

112. A method of claim 109, wherein the paramagnetic ion is iron.

113. A method of claim 109, wherein the paramagnetic ion is chelated by an aminopolycarboxylic acid.

114. A method of claim 109, wherein no free acid or free base groups are present in the chelate complex.

115. A method of claim 109, wherein a free acid or a free base group is present in the chelate complex.

116. A method of claim 109, wherein a free acid or a free base group of the chelate complex is in the form of a salt thereof with an inorganic or organic base or acid.

117. A method of claim 109, wherein the paramagnetic ion is chelated by an open-chain chelating agent.

118. A method of claim 109, wherein the paramagnetic ion is chelated by a cyclic chelating agent.

119. A method of claim 109, wherein said chelate complex is both a salt of said paramagnetic ion and the chelate complexing agent thereof, and also a salt with an inorganic or organic base or acid.

120. A method of claim 109, wherein said chelate complex is only a salt of said paramagnetic ion and the chelate complexing agent thereof and not also a salt with an inorganic or organic base or acid.

121. A method of claim 112, wherein the paramagnetic ion is Fe(II).

122. A method of claim 109, wherein the patient is a human.

123. A method of claim 109, wherein the chelate complex is nonionic.

124. A method according to claim 109, wherein said biomolecule is an immunoglobulin.

125. A method according to claim 109, wherein said biomolecule is a hormone.

126. A method according to claim 109, wherein said biomolecule is a protein.

127. A method according to claim 109, wherein said biomolecule is a peptide.

128. A method according to claim 109, wherein said biomolecule is a lipid.

129. A method of enhancing an NMR image, comprising obtaining an enhanced NMR image by NMR imaging a human to whom there has been administered an amount, effective to enhance NMR image contrast, of a physiologically compatible chelate complex of a paramagnetic ion, said chelate complex being bound to a biomolecule effective to transport said chelate complex to a specific site in said patient.

130. A method of claim 129, wherein the complex is formulated together with a pharmaceutically acceptable carrier.

131. A method of claim 130, wherein the paramagnetic ion is Gd(III).

132. A method of claim 130, wherein the paramagnetic ion is Mn(II).

133. A method of claim 130, wherein the paramagnetic ion is iron.

134. A method of claim 130, wherein the paramagnetic ion is chelated by an aminopolycarboxylic acid.

135. A method of claim 130, wherein no free acid or free base groups are present in the chelate complex.

136. A method of claim 130, wherein a free acid or a free base group is present in the chelate complex.

137. A method of claim 130, wherein a free acid or a free base group of the chelate complex is in the form of a salt thereof with an inorganic or organic base or acid.

138. A method of claim 130, wherein the paramagnetic ion is chelated by an open-chain chelating agent.

139. A method of claim 130, wherein the paramagnetic ion is chelated by a cyclic chelating agent.

140. A method of claim 130, wherein said chelate complex is both a salt of said paramagnetic ion and the chelate complexing agent thereof, and also a salt with an inorganic or organic base or acid.

141. A method of claim 130, wherein said chelate complex is only a salt of said paramagnetic ion and the chelate complexing agent thereof and not also a salt with an inorganic or organic base or acid.

142. A method of claim 133, wherein the paramagnetic ion is Fe(II).

143. A method of claim 130, wherein the chelate complex is nonionic.

144. A method according to claim 130, wherein said biomolecule is an immunoglobulin.

145. A method according to claim 130, wherein said biomolecule is a hormone.

146. A method according to claim 130, wherein said biomolecule is a protein.

147. A method according to claim 130, wherein said biomolecule is a peptide.

148. A method according to claim 130, wherein said biomolecule is a lipid.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc